Although it was expected that this elimination should provide a single isomer from the pure diastereomer 12, a partial E, elimination through a benzyl anion intermediate resulted in the formation of the mixture of two dienes. The conformational analysis of 6A based on MM2* calculations (see Scheme 2) predicts that the dominant conformation (>95%) has a twisted diene moiety and an axial orienration of the alkyne side chain at C(2). Attack of the dienophile from the less hindered convex p-face of the diene can explain the slightly preferential formation of 5 . These calculations also suggest "remote control" of the Diels-Alder reaction of 6A, in which intermediate binding of the dienophile (acetylenedicarboxylate) to the alkynyl group attached to the diene moiety in 6a, would help produce compound 5 as the sole product. Crystal structure data of 14: monoclinic, space group P2,/a, N = 11.888(4), h = 27.454(8). r = 10.509(3) A, p =103.68(2)', V = 3333(2) A3. Z = 4: pca,cd = 1.16 gcm-3; 4705 measured reflections, 2525 classed as observed with I2 3.0u(!). Solution of structure by direct methods (Monte-Carlo MUL-TAN), R = 0.073. Further details of the crystal structure investigation may be
[reaction: see text] New air-stable PdCl(2){P(t)Bu(2)(p-R-Ph)}(2) (R = H, NMe(2), CF(3),) complexes represent simple, general, and efficient catalysts for the Suzuki-Miyaura cross-coupling reactions of aryl halides including five-membered heteroaryl halides and heteroatom-substituted six-membered heteroaryl chlorides with a diverse range of arylboronic acids. High product yields (89-99% isolated yields) and turn-over-numbers (10,000 TON) are observed.
The phenyl backbone-derived P,O-ligands 1 and 2 were investigated for their utility as ligands in palladium/ligand-catalyzed Suzuki reactions. The 2-(2'-dicyclohexylphosphinophenyl)-2-methyl-1,3-dioxolane (ligand 1) in combination with Pd(dba)(2) affords an efficient catalyst for general Suzuki reactions of a wide variety of arylboronic acids and aryl chlorides, bromides, and iodides to afford the desired biaryl products in high isolated yields. Arylboronic acids and aryl chlorides containing electron-poor, electron-rich, and ortho substituents participate effectively. In contrast, the structurally related ligand 2-(2'-dicyclohexylphosphinophenyl)-1,3-dioxolane (ligand 2) was found to be less efficient under similar conditions. The reaction of ligand 1 with Pd(dba)(2) affords the complex LPd(dba) (14, L = 1). The NMR spectroscopic and X-ray crystallographic data of complex 14 establish that ligand 1 functions as a P,O-chelating ligand in complex 14. The reaction of ligand 2 (2 equiv) with Pd(dba)(2) and excess 4-(t)()Bu-C(6)H(4)Br or the ligand displacement reaction of {Pd[P(o-tolyl)(3)](4-(t)()Bu-C(6)H(4))(&mgr;-Br)}(2) with ligand 2 affords the bis-phosphine complex L(2)Pd(4-(t)()Bu-C(6)H(4))(Br) (13, L = 2). The NMR spectroscopic data of complex 13 establish that ligand 2 in complex 13 functions as a nonchelating ligand. Thus, the higher efficiency of ligand 1 over ligand 2 in Pd/L-catalyzed Suzuki arylation of aryl chlorides can be ascribed to the ability of ligand 1 to generate and stabilize mono-phosphine P,O-chelating Pd/L intermediates, which appear to be most suitable for Suzuki arylation reactions involving certain substrates and conditions.
The new air-stable PdCl2[PR2(Ph-R')]2 complexes, readily prepared from commercial reagents, exhibit unique efficiency as catalysts for the Suzuki-Miyaura coupling reactions of a variety of heteroatom-substituted heteroaryl chlorides with a diverse range of aryl/heteroaryl boronic acids. The coupling reactions catalyzed by the new complexes exhibit high product yields (88-99%) and high catalyst turnover numbers (up to 10,000 TON).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.